TY - JOUR
T1 - Different effects of chronic omeprazole use on osteoporotic fractures rate in the elderly
AU - Gingold-Belfer, Rachel
AU - Beloosesky, Yichayaou
AU - Amara, Amir
AU - Sharon, Eran
AU - Boltin, Doron
AU - Koren-Morag, Nira
AU - Meyerovitch, Joseph
AU - Schmilovitz-Weiss, Hemda
N1 - Publisher Copyright:
© 2023 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
PY - 2023/12
Y1 - 2023/12
N2 - Aims: To investigate the potential association of chronic use of omeprazole with the occurrence of osteoporotic fractures (OF) in community-dwelling elderly subjects. Methods: The cohort consisted of community-dwelling residents aged >65 years registered with a large health maintenance organization in Israel between January 2002 and December 2016. Data were retrospectively collected from the electronic medical files on demographics, parameters known to be associated with OF, diagnoses of osteoporotic hip, wrist, and vertebral fractures, and chronic use of omeprazole (>11 prescriptions/year). Time to OF/death/end of study was calculated from the beginning of the study (2002). The risk of fractures in the chronic users of omeprazole was analyzed by multivariate Cox proportional hazard regression model. Results: In total, 46 805 subjects were included (41% men), mean age 83.4±6.4 years, of whom 10 272 (21.9%) were chronic users of omeprazole. During 14 years of follow-up, OF were diagnosed in 414 (4.0%) omeprazole users and 1007 (2.8%) omeprazole nonusers (p < 0.001). In a Cox regression model adjusted for age and gender only, chronic use of omeprazole was associated with a 16% excess of OF. However, when parameters known to be associated with OF were entered into the multivariate Cox regression model, chronic use of omeprazole was not found to be an independent risk factor for OF, either overall (adjusted hazard ratio = 0.965, 95% confidence interval 0.86–1.08, P =.55) or specifically, in the ≥85 years age group (adjusted hazard ration = 0.780, 95% confidence interval 0.635–0.958, P <.05) in which an inverse correlation between omeprazole use and OF, was demonstrated. Conclusions: Chronic use of omeprazole was not associated with the occurrence of OF in elders.
AB - Aims: To investigate the potential association of chronic use of omeprazole with the occurrence of osteoporotic fractures (OF) in community-dwelling elderly subjects. Methods: The cohort consisted of community-dwelling residents aged >65 years registered with a large health maintenance organization in Israel between January 2002 and December 2016. Data were retrospectively collected from the electronic medical files on demographics, parameters known to be associated with OF, diagnoses of osteoporotic hip, wrist, and vertebral fractures, and chronic use of omeprazole (>11 prescriptions/year). Time to OF/death/end of study was calculated from the beginning of the study (2002). The risk of fractures in the chronic users of omeprazole was analyzed by multivariate Cox proportional hazard regression model. Results: In total, 46 805 subjects were included (41% men), mean age 83.4±6.4 years, of whom 10 272 (21.9%) were chronic users of omeprazole. During 14 years of follow-up, OF were diagnosed in 414 (4.0%) omeprazole users and 1007 (2.8%) omeprazole nonusers (p < 0.001). In a Cox regression model adjusted for age and gender only, chronic use of omeprazole was associated with a 16% excess of OF. However, when parameters known to be associated with OF were entered into the multivariate Cox regression model, chronic use of omeprazole was not found to be an independent risk factor for OF, either overall (adjusted hazard ratio = 0.965, 95% confidence interval 0.86–1.08, P =.55) or specifically, in the ≥85 years age group (adjusted hazard ration = 0.780, 95% confidence interval 0.635–0.958, P <.05) in which an inverse correlation between omeprazole use and OF, was demonstrated. Conclusions: Chronic use of omeprazole was not associated with the occurrence of OF in elders.
KW - elders
KW - omeprazole use
KW - osteoporotic fractures
UR - http://www.scopus.com/inward/record.url?scp=85166741637&partnerID=8YFLogxK
U2 - 10.1111/bcp.15847
DO - 10.1111/bcp.15847
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 37463830
AN - SCOPUS:85166741637
SN - 0306-5251
VL - 89
SP - 3539
EP - 3550
JO - British Journal of Clinical Pharmacology
JF - British Journal of Clinical Pharmacology
IS - 12
ER -